Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharming Group N.V (PHAR) EBITDA: 2020-2025

Historic EBITDA for Pharming Group N.V (PHAR) over the last 4 years, with Sep 2025 value amounting to $90.2 million.

  • Pharming Group N.V's EBITDA rose 2096.11% to $90.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $104.8 million, marking a year-over-year increase of 442.95%. This contributed to the annual value of -$8.6 million for FY2024, which is 60.03% down from last year.
  • According to the latest figures from Q3 2025, Pharming Group N.V's EBITDA is $90.2 million, which was up 2,270.99% from $3.8 million recorded in Q2 2025.
  • In the past 5 years, Pharming Group N.V's EBITDA ranged from a high of $90.2 million in Q3 2025 and a low of -$19.4 million during Q2 2024.
  • In the last 3 years, Pharming Group N.V's EBITDA had a median value of $1.5 million in 2023 and averaged $5.0 million.
  • In the last 5 years, Pharming Group N.V's EBITDA spiked by 44,862.60% in 2022 and then slumped by 584.96% in 2023.
  • Over the past 5 years, Pharming Group N.V's EBITDA (Quarterly) stood at $13.5 million in 2021, then slumped by 175.13% to -$10.2 million in 2022, then skyrocketed by 110.50% to $1.1 million in 2023, then spiked by 527.13% to $6.7 million in 2024, then spiked by 2,096.11% to $90.2 million in 2025.
  • Its EBITDA stands at $90.2 million for Q3 2025, versus $3.8 million for Q2 2025 and $6.7 million for Q4 2024.